Barclays analyst Manav Patnaik maintains Dun & Bradstreet Hldgs (NYSE:DNB) with a Equal-Weight and lowers the price target from $18 to $17.
Filament Health Shares Q1 2023 Financials, Material Uncertainties Upon Securing Additional Financing
Natural psychedelic drug development company Filament Health (OTCQB: FLHLF) has released its unaudited consolidated, condensed financial results for Q1 2023 ended June 30.
Numbers show: